April 09, 2020
1 min read
Save

Convalescent plasma transfusion shows promise for COVID-19, plus more top stories in hematology/oncology

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Preliminary results of an uncontrolled case series in China showed that convalescent plasma therapy may help improve the clinical outcomes of patients with severe disease related to COVID-19. It was the top story in hematology/oncology last week.

Another top story was about a case study that suggests tocilizumab (Actemra, Genentech) may be an effective treatment for patients with COVID-19 and hematologic malignancies; however, more research is needed to further evaluate the safety and efficacy of the immunosuppressant in this setting.

Read these and more top stories in hematology/oncology below:

Convalescent plasma transfusion shows promise for severely ill patients with COVID-19

Preliminary research has shown the potential of convalescent plasma therapy to improve clinical outcomes of patients with severe disease related to COVID-19. Read more.

Tocilizumab may be effective for patients with COVID-19, blood cancer

The immunosuppressant tocilizumab may be an effective treatment for very ill individuals with COVID-19 and hematologic malignancies, according to results of a case study from China published in Blood Advances. Read more.

 
Preliminary research has shown the potential of convalescent plasma therapy to improve clinical outcomes of patients with severe disease related to COVID-19.
Source: Adobe Stock

Blood test detects dozens of cancer types, often before symptoms emerge

A novel blood test accurately detected more than 50 types of cancer with a specificity of 99.3%, according to results of the prospective Circulating Cell-free Genome Atlas study published in Annals of Oncology. Read more.

FDA clears IND application for natural killer cell-based COVID-19 therapy

The FDA cleared an investigational new drug application for CYNK-001 for the treatment of adults with COVID-19 infection, according to the agent’s manufacturer. Read more.

Researchers to collaborate on natural killer cell-based COVID-19 treatment

Green Cross LabCell, a South Korea-based biopharmaceutical company, announced it will begin development of a COVID-19 treatment based on its anticancer therapy work using natural killer cells. Read more.